| Income Statement | 2025-09-30 | 2024-09-30 | ||
|---|---|---|---|---|
| Net revenue | 236.561 | 236.56 | ||
| Research and development | 11.725 | 153.685 | ||
| General and administrative | 75.113 | 58.92 | ||
| Consulting and professional fees | 398.263 | 363.961 | ||
| Rent | 90 | 77.215 | ||
| Total operating expenses | 575.101 | 653.781 | ||
| Loss from operations | -338.54 | -417.221 | ||
| Unrealized gain ( loss) on sale of investment securities | - | 0 | ||
| Interest expense attributable to amortization of discount | - | 57.996 | ||
| Interest expense | 158.286 | 72.445 | ||
| Interest expense attributable to amortization of discount | 52.148 | 28.998 | ||
| Financing fees | - | 145.5 | ||
| Derivative income (expense) | -675.528 | -4.091 | ||
| Adjustment | - | 57.996 | ||
| Penalties | 50 | - | ||
| Total other income (expense), net | -935.962 | -251.034 | ||
| Net loss before income taxes | -1,274.502 | -668.255 | ||
| Income tax provision | 0 | - | ||
| Net loss | -1,274.502 | -668.255 | ||
| Net loss per common share, basic | -0.05 | -0.16 | ||
| Net loss per common share, diluted | -0.05 | -0.16 | ||
| Number of weighted average shares - basic | 23,521,970 | 4,110,265 | ||
| Number of weighted average shares - diluted | 23,521,970 | 4,110,265 | ||
Regen BioPharma Inc (RGBP)
Regen BioPharma Inc (RGBP)